Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include very common findings: Delayed speech and language development and Abnormal speech pattern; and common findings: Deficit in grammar, Incomprehensible speech, Dysarthria, and Specific learning disability and others. 25 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 11 | Delayed speech and language development, Incomprehensible speech, Abnormal speech pattern |
Muscles | 2 | Shrinkage of the caudate nucleus (brain) (caudate atrophy), Poor gross motor coordination |
Head and neck | 2 | Submucous cleft hard palate, High, narrow palate |
Digestive system | 1 | Feeding difficulties |
Available evidence to date suggests that FOXP2-related speech and language disorder (FOXP2-SLD) is caused by heterozygous FOXP2 pathogenic variants (including whole- or partial-gene deletions). FOXP2-SLD has a core phenotype: childhood apraxia of speech (CAS), a disorder of speech motor programming or planning that affects the production, sequencing, timing, and stress of sounds, and the accurate sequencing of speech sounds into syllables and syllables into words. In addition, CAS interferes nonselectively with multiple other aspects of language, including phonology, grammar, and literacy. The interactions between these communication disorder subtypes are not well understood.
Source: GeneReviews — "FOXP2-Related Speech and Language Disorder"
FOXP2 encodes forkhead box P2 (715 aa). Transcriptional repressor that may play a role in the specification and differentiation of lung epithelium. May also play a role in developing neural, gastrointestinal and cardiovascular tissues. Highest expression in Colon Sigmoid (14.7 TPM) and Esophagus Gastroesophageal Junction (7.0 TPM).
Childhood apraxia of speech is associated with mutations in the FOXP2 gene on chromosome 7.
The FOXP2 protein participates in Positive Regulation of CDH1 Gene Transcription, Regulation of CDH1 Gene Transcription, and FOXA2 stimulates CDH1 gene transcription pathways.
FOXP2 is classified as a druggable target (Transcription Factor category) with score 0.0.
The penetrance for FOXP2-SLD is high – close to 100% – based on the findings in individuals reported to date .
Source: GeneReviews — "FOXP2-Related Speech and Language Disorder"
No consensus clinical diagnostic criteria for FOXP2-related speech and language disorder (FOXP2-SLD) have been published.
FOXP2-SLD should be suspected in a child with the following clinical findings and family history.
Childhood apraxia of speech (CAS) (also known as developmental verbal dyspraxia, verbal dyspraxia, or speech dyspraxia)
Source: GeneReviews — "FOXP2-Related Speech and Language Disorder"
The prelinguistic developmental history of children with childhood apraxia of speech (CAS) (e.g., restricted babbling or feeding difficulties) is very similar to that seen in other neurodevelopmental speech or language conditions (e.g., developmental language disorder, phonologic disorder) or even other neurodevelopmental disorders in which language impairment may occur such as autism spectrum disorder. Hence, early signs are not usually sufficiently discriminating to enable a differential diagnosis prior to a child gaining some speech production abilities. While CAS is rare, it may also be observed in a range of other conditions. The following chromosomal and single-gene disorders may be considered in the differential diagnosis. Chromosomal disorders associated with CAS include:
Source: GeneReviews — "FOXP2-Related Speech and Language Disorder"
Genetic testing for FOXP2 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for childhood apraxia of speech has been reported in the published literature.
No approved treatments are currently available for childhood apraxia of speech. The disease remains an area of unmet medical need.
Gene therapy approaches for childhood apraxia of speech have been reported in the published literature.
No clinical practice guidelines for FOXP2-related speech and language disorder (FOXP2-SLD) have been published.
To establish the extent of disease and management needs for an individual with FOXP2-SLD, the following evaluations conducted by a trained and specialized speech-language pathologist are recommended:
Source: GeneReviews — "FOXP2-Related Speech and Language Disorder"
8 trials found
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the following evaluations are recommended:
Routine care by a general pediatrician
Follow-up evaluations with standardized tests by a speech-language pathologist
Review educational progress/needs
Review mental health if anxiety and/or depression have been issues or have emerged as issues
Source: GeneReviews — "FOXP2-Related Speech and Language Disorder"
Phenotype severity distribution: 2 very common features, 10 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
8 clinical trials registered, 2 recruiting. Interventions under study include other interventions and drug therapy. Pipeline includes 1 PHASE2, 1 PHASE1, 6 NA. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT04642053](https://clinicaltrials.gov/study/NCT04642053) | A Randomized Control Trial of Motor-based Intervention for CAS | NA | New York University | ACTIVE_NOT_RECRUITING |
[NCT05916222](https://clinicaltrials.gov/study/NCT05916222) | The Effects of Caregiver Training on DTTC Treatment Outcomes in CAS | NA | New York University | ACTIVE_NOT_RECRUITING |
[NCT07087249](https://clinicaltrials.gov/study/NCT07087249) | Efficacy of Ultrasound Biofeedback in Brazilian Childhood Apraxia of Speech | NA | Aline Mara de Oliveira | NOT_YET_RECRUITING |
[NCT05066178](https://clinicaltrials.gov/study/NCT05066178) | Speech Treatment for Minimally Verbal Children With ASD and CAS | NA | MGH Institute of Health Professions | RECRUITING |
[NCT07526246](https://clinicaltrials.gov/study/NCT07526246) | Motor-based Intervention for Childhood Apraxia of Speech: DTTC-Connect | NA | New York University | RECRUITING |
142 publications have been identified in PubMed for childhood apraxia of speech. Research spans Basic Science / Preclinical (24%), Review / Meta-Analysis (21%), and Diagnostic / Biomarker (17%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 31 | 24% |
Research summaries | 27 | 21% |
Testing and diagnosis research | 22 | 17% |
Disease patterns and progression | 17 | 13% |
Patient case studies | 16 | 12% |
Clinical study results | 12 |
Garrett AJ (2026). [PMID: 41937368](https://pubmed.ncbi.nlm.nih.gov/41937368/). *Int J Lang Commun Disord*. [Review / Meta-Analysis]
Baas BS (2026). [PMID: 41686715](https://pubmed.ncbi.nlm.nih.gov/41686715/). *Cleft Palate Craniofac J*. [Clinical Trial Publication]
Zhang Z (2026). [PMID: 41661187](https://pubmed.ncbi.nlm.nih.gov/41661187/). *Psychiatr Genet*. [Case Report / Case Series]
Valentine HC (2026). [PMID: 41386789](https://pubmed.ncbi.nlm.nih.gov/41386789/). *Am J Speech Lang Pathol*. [Basic Science / Preclinical]
Borrie SA (2026). [PMID: 42189765](https://pubmed.ncbi.nlm.nih.gov/42189765/). *Am J Speech Lang Pathol*. [Clinical Trial Publication]
Nealon K (2026). [PMID: 42096720](https://pubmed.ncbi.nlm.nih.gov/42096720/). *Am J Speech Lang Pathol*. [Epidemiology / Natural History]
Adams S (2026). [PMID: 41649066](https://pubmed.ncbi.nlm.nih.gov/41649066/). *Augment Altern Commun*. [Review / Meta-Analysis]
St John M (2026). [PMID: 41665066](https://pubmed.ncbi.nlm.nih.gov/41665066/). *Cochrane Database Syst Rev*. [Review / Meta-Analysis]
Haley KL (2026). [PMID: 40314430](https://pubmed.ncbi.nlm.nih.gov/40314430/). *Clin Linguist Phon*. [Basic Science / Preclinical]
Mogren Å (2026). [PMID: 42152575](https://pubmed.ncbi.nlm.nih.gov/42152575/). *Logoped Phoniatr Vocol*. [Epidemiology / Natural History]
Data assembled from 8 of 12 sources · Last updated Sep 20, 2026, 9:31 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about childhood apraxia of speech
Other research | 3 | 2% |
New treatment approaches | 2 | 2% |
AI-curated news mentioning childhood apraxia of speech
Updated May 18, 2026
A recent study published in PubMed highlights differences in non-word repetition, oral-motor performance, and auditory discrimination between children with childhood apraxia of speech and those with speech motor delay. These findings could inform targeted interventions for these distinct speech disorders.